Abstract
Background
To evaluate experience of the use of temsirolimus for metastatic renal cell carcinoma (mRCC) in a single center in Japan.
Methods
This study included 55 consecutive patients with mRCC who received temsirolimus in a routine clinical setting, and retrospectively reviewed the comprehensive outcomes of these patients.
Results
Of the 55 patients, 20 had a Karnofsky performance status of ≤80, and 5, 41 and 9 were classified into favorable, intermediate and poor risk groups, respectively, according to the Memorial Sloan-Kettering Cancer Center model. Initially, 25 mg of temsirolimus was applied weekly; however, dose modification was required in 19 patients, resulting in a relative dose intensity of 90.5 % throughout this series. As the best responses to temsirolimus, 4, 44 and 7 were judged to have a partial response, stable disease and progressive disease, respectively. The median progression-free survival (PFS) and overall survival (OS) of these patients following the introduction of temsirolimus was 7.0 and 25.0 months, respectively. Of several factors examined, only the pretreatment C-reactive protein level was shown to be independently associated with both PFS and OS. The common adverse events related to temsirolimus corresponding to ≥grade 3 were anemia in 4, thrombocytopenia in 3, stomatitis in 3 and hyperglycemia in 3. Quality of life analysis using 36-Item Short Form showed that there were no significant differences in any scale scores between surveys performed before and 3 months after the introduction of temsirolimus.
Conclusions
Temsirolimus was well tolerated and facilitated comparatively favorable cancer control in Japanese patients with mRCC.
Similar content being viewed by others
References
Parton M, Gore M, Eisen T (2006) Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24:5584–5592
Bellmunt J, Montagut C, Albiol S et al (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99:274–280
Chowdhury S, Larkin JM, Gore ME (2008) Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 44:2152–2162
Fasolo A, Sessa C (2012) Targeting mTOR pathways in human malignancies. Curr Pharm Des 18:2766–2777
Sheppard K, Kinross KM, Solomon B et al (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17:69–95
Shor B, Zhang WG, Toral-Barza L et al (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934–2943
Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296
Fukuhara S, Bito S, Green J (1998) Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol 51:1037–1044
Fukuhara S, Ware JE Jr, Kosinski M (1998) Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol 51:1045–1053
Sun Y, Rha S, Lee SH et al (2012) Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol 42:836–844
Miyake H, Harada KI, Kusuda Y et al (2012) Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. Int J Clin Oncol (Epub ahead of print)
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134
Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
Uemura H, Shinohara N, Yuasa T et al (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194–202
Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939
Ueda T, Uemura H, Tomita Y et al (2013) Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 43:616–628
Lamm W, Vogl UM, Bojic M et al (2012) Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncol 51:101–106
Kuru TH, Huber J, Hatiboglu G et al (2011) Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response. Urol Int 86:256–260
Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463
Maroto JP, Hudes G, Dutcher JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29:1750–1756
Cella D, Li JZ, Cappelleri JC et al (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon α: results from a phase III randomized trial. J Clin Oncol 26:3763–3769
Miyake H, Kurahashi T, Yamanaka K et al (2010) Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int 106:1643–1647
Yang S, de Souza P, Alemao E et al (2010) Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. Br J Cancer 102:1456–1460
Conflict of interest
Hideaki Miyake and Masato Fujisawa received lecture fees from Pfizer.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Miyake, H., Harada, Ki., Kumano, M. et al. Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan. Int J Clin Oncol 19, 679–685 (2014). https://doi.org/10.1007/s10147-013-0617-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-013-0617-7